Journal article

A beta and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease

Yen Ying Lim, Paul Maruff, Robert H Pietrzak, Kathryn A Ellis, David Darby, David Ames, Karra Harrington, Ralph N Martins, Colin L Masters, Cassandra Szoeke, Greg Savage, Victor L Villemagne, Christopher C Rowe

Alzheimers Dement | ELSEVIER SCIENCE INC | Published : 2014


Funding Acknowledgements

Funding for the study was provided in part by the study partners (CSIRO; Edith Cowan University; the Mental Health Research Institute; Alzheimer's Australia; the National Ageing Research Institute; Austin Health, CogState, Ltd.; Hollywood Private Hospital; Sir Charles Gardner Hospital). The study also received support from the National Health and Medical Research Council (NHMRC) and the Dementia Collaborative Research Centres program as well as ongoing funding from the Science and Industry Endowment Fund.Y.Y.L., K.E., K.H., C.M., and G.S. report no disclosures. R.P. and D.D. are scientific consultants to CogState, Ltd., the company that provided the CogState battery of tests used in this study. D.D. is a shareholder of stock in CogState, Ltd. D.A. has served on scientific advisory boards for Novartis, Eli Lilly, Janssen, and Pfizer Inc.; has received funding for travel from Janssen and Pfizer Inc., has served as Editor-in-Chief for International Psychogeriatrics; has received speaker honoraria from Pfizer, Inc., and Lundbeck, Inc.; and has received research support from Eli Lilly and Company, GlaxoSmithKline, Forest Laboratories, Inc., Novartis, and CSIRO. A.B. is a paid consultant for Synthetic Biologics and holds equity in Prana Biotechnology, Ltd.; CogState, Ltd.; and Eucalyptus Biosciences Pty Ltd. R.M. has served as Senior Editor of the Journal of Alzheimer's Disease for 1 year and previously as a review editor for 3 years; has served as a consultant to a small biotech company, Alzhyme, but currently no financial benefits or fees are accepted; has received CSIRO flagship funding for 3 years at

million per year; and holds stock for a small biotech company, Alzhyme, which is not listed. C.R. serves on scientific advisory boards for Bayer Schering Pharma, Elan Corporation, and AstraZeneca; has received speaker honoraria from Bayer Schering Pharma; and receives research support from Bayer Schering Pharma, Avid Radiopharmaceuticals, Inc., CSIRO, and the Alzheimer's Association. C.S. has previously been a clinical consultant and received speaker honorario from Pfizer, Sanofi-Aventis, Mayne Pharma, and Lundbeck; has been employed as Commercial Entity Clinical Consultant for CSIRO Preventative Health; and served as NHMRC Chief Investigator in 2009 and 2010. Academic entities: National Ageing Research Institute, University of Melbourne, Melbourne Health; research support, foundations, and societies: ESA, Epilepsy Fellowship, 2007 Bio21, Pharmacogenetics Overseas Training Scholarship, 2008 RACP, PostDoc Scholarship, 2007 Alzheimer's Association of Australia, Research Fellow, 2008-2010, Scobie and Claire McKinnon Foundation, chief investigator, 2009, Collier Foundations, chief investigator, 2009, and Brain Foundation, chief investigator, 2010. V.V. serves on the editorial board of the Journal of Alzheimer's Disease; serves as a consultant for Bayer Schering Pharma; and receives research support from NHMRC and NEDO, Japan. P.M. is a full-time employee of CogState, Ltd.